Results 21 to 30 of about 399,367 (396)

A unique three-way Philadelphia chromosome variant t(4;9;22)(q21;q34;q11.2) in a newly diagnosed patient with chronic phase chronic myeloid leukemia: a case report and review of the literature

Journal of Medical Case Reports, 2021
Background Chronic myeloid leukemia is a hematologic malignancy associated with the fusion of two genes: BCR and ABL1. This fusion results from a translocation between chromosomes 9 and 22, which is called the Philadelphia chromosome.
Yuka Torii, Kana Nanjo, Tomomi Toubai, Masashi Hosokawa, Ryo Sato, Akane Yamada, Keiko Aizawa, Masahito Himuro, Satoshi Ito, Masakazu Yamamoto, John Magenau, Ryan Wilcox, Kenichi Ishizawa   +12 more
doaj   +1 more source

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

American journal of hematology/oncology, 2020
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults.
E. Jabbour, H. Kantarjian
semanticscholar   +1 more source

Bosutinib for Chronic Myeloid Leukemia [PDF]

Rare Cancers and Therapy, 2015
In recent years the availability of several tyrosine kinase inhibitors (TKI) in the therapeutic armamentarium for chronic myeloid leukemia has dramatically changed the objectives and expectations of healthcare providers and patients. For many, but not all, patients the forerunner of TKI, imatinib, is still an excellent treatment option.
Massimo Breccia, Gianni Binotto
openaire   +3 more sources

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

New England Journal of Medicine, 2003
BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa.
S. O’Brien, F. Guilhot, R. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J. L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A. Bolton, R. Capdeville, B. Druker   +24 more
semanticscholar   +1 more source

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2020
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene.
M. Deininger, Neil P. Shah, Jessica K. Altman, E. Berman, R. Bhatia, B. Bhatnagar, D. DeAngelo, J. Gotlib, G. Hobbs, L. Maness, M. Mead, L. Metheny, S. Mohan, Joseph O. Moore, K. Naqvi, V. Oehler, A. Pallera, M. Patnaik, K. Pratz, I. Pusic, Michal G. Rose, B. D. Smith, David S. Snyder, K. Sweet, M. Talpaz, James E. Thompson, David T. Yang, K. Gregory, Hema M Sundar   +28 more
semanticscholar   +1 more source

A dual origin for Bcr-Abl gene translocation/fusion as dynamics of synergism of the hematopoietic stem cell and hemangioblast in chronic myeloid leukemia [PDF]

, 2015
Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic ...
Agius, Lawrence M.
core   +1 more source

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Blood, 2013
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update recommendations made in ...
M. Baccarani, M. Deininger, G. Rosti, A. Hochhaus, S. Soverini, J. Apperley, F. Cervantes, R. Clark, J. Cortes, F. Guilhot, H. Hjorth-Hansen, T. Hughes, H. Kantarjian, Dong-Wook Kim, R. Larson, J. Lipton, F. Mahon, G. Martinelli, J. Mayer, Martin C. Müller, D. Niederwieser, F. Pane, J. Radich, P. Rousselot, G. Saglio, S. Saussele, C. Schiffer, R. Silver, B. Simonsson, J. Steegmann, J. Goldman, R. Hehlmann   +31 more
semanticscholar   +1 more source

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]

, 2018
The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core   +1 more source

Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor

Haematologica, 2008
Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumorpatients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few ...
Rita Santachiara, Rossana Maffei, Silvia Martinelli, Annalisa Arcari, Federico Piacentini, Elena Trabacchi, Pierluigi Alfieri, Angela Ferrari, Giovanna Leonardi, Gabriele Luppi, Giuseppe Longo, Daniele Vallisa, Roberto Marasca, Giuseppe Torelli   +13 more
doaj   +1 more source

Report of an Unusual Case: Testicular Involvement of Chronic Myeloid Leukemia 10 Years after the Complete Response [PDF]

Journal of Clinical and Diagnostic Research, 2014
Testicular extra-medullary myeloid cell tumours are rare tumours presenting in most cases with painless testicular swelling. We present here a case of 21-year-old man with painless scrotal swelling.
Cem Nedim Yuceturk, Berat Cem Ozgur, Hasmet Sarici, Pelin Borcek, Onur Telli   +4 more
doaj   +1 more source